# NCT05445908 (NCT05445908)

> SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05445908
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Triple-negative Breast Cancer and HR+/HER2- BC
- Interventions: SKB264; KL-A167
- Enrollment: 184
- Primary outcome: Incidence and severity of adverse events (AEs)
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on NCT05445908 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05445908